A detailed history of Core Alternative Capital transactions in Abb Vie Inc. stock. As of the latest transaction made, Core Alternative Capital holds 3,787 shares of ABBV stock, worth $761,944. This represents 0.13% of its overall portfolio holdings.

Number of Shares
3,787
Previous 3,795 0.21%
Holding current value
$761,944
Previous $691,000 6.08%
% of portfolio
0.13%
Previous 0.12%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 16, 2024

SELL
$154.79 - $180.76 $1,238 - $1,446
-8 Reduced 0.21%
3,787 $649,000
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $123,381 - $140,581
-772 Reduced 16.9%
3,795 $691,000
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $140,076 - $157,759
-1,018 Reduced 18.23%
4,567 $707,000
Q3 2023

Oct 19, 2023

BUY
$133.59 - $154.65 $399,166 - $462,094
2,988 Added 115.06%
5,585 $832,000
Q2 2023

Jul 27, 2023

BUY
$132.51 - $164.9 $23,321 - $29,022
176 Added 7.27%
2,597 $349,000
Q1 2023

Apr 18, 2023

BUY
$144.61 - $166.54 $13,014 - $14,988
90 Added 3.86%
2,421 $385,000
Q4 2022

Jan 31, 2023

SELL
$138.31 - $165.87 $55,462 - $66,513
-401 Reduced 14.68%
2,331 $376,000
Q3 2022

Oct 18, 2022

SELL
$134.21 - $153.93 $20,936 - $24,013
-156 Reduced 5.4%
2,732 $367,000
Q2 2022

Aug 01, 2022

BUY
$137.62 - $174.96 $148,629 - $188,956
1,080 Added 59.73%
2,888 $442,000
Q1 2022

May 10, 2022

BUY
$131.98 - $163.75 $196,650 - $243,987
1,490 Added 468.55%
1,808 $293,000
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $6,445 - $8,155
60 Added 23.26%
318 $43,000
Q3 2021

Nov 05, 2021

BUY
$106.4 - $120.78 $27,451 - $31,161
258 New
258 $28,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $356B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Core Alternative Capital Portfolio

Follow Core Alternative Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Alternative Capital, based on Form 13F filings with the SEC.

News

Stay updated on Core Alternative Capital with notifications on news.